Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

AJMC

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

By Brigham Walker, PhD
Lalan Wilfong, MD

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 23rd 2015

Expert Analysis on Managing mCRC

At the 26th International Congress on Anti-Cancer Treatment in Paris, France, earlier this month, oncologists deliberated on the current understanding of metastatic colorectal cancer and the available treatment options. Recent work has shown that there are 4 or 5 different subtypes of the disease, which may call for personalized therapeutic strategies.

February 21st 2015

Managed Care Minute: February 21, 2015

A one-minute look at managed care news during the week of February 16, 2015, including extended open enrollment under the Affordable Care Act and shared decision-making for cancer treatments.

February 20th 2015

Celgene's Revlimid Receives Expanded Approval in Europe Following Similar FDA Approval

After the FDA approved lenalidomide for use in chemotherapy-naive multiple myeloma (MM) patients, the European Commission has followed suit. Revlimid was approved today by EC in MM patients, previously untreated and transplant-ineligible.

February 20th 2015

Study Underscores the Potential of Mobile Health App in Healthcare Decisions

The study, conducted at the Columbia University School of Nursing, found that mobile apps with decision support features resulted in significantly higher diagnosis rates than apps with only bare-bones tools for recording results from a patient exam.

February 20th 2015

UCLA Study Points to Need for Informed Decision-Making in Prostate Cancer

The study evaluated SEER data of over 37,000 prostate cancer patients and found an overwhelming majority of patients (58%) received radiation treatment regardless of overall disease prognosis. The lead study author hopes these findings enlighten the public and allow physicians to make an informed decision when it comes to the best treatment option for men who may or may not benefit from radiation therapy in the long run.

February 20th 2015

FDA Authorizes Sale of First Direct-to-Consumer Genetic Test

Developed by the company 23andMe, the test identifies carriers of a gene mutation that could determine the susceptibility of a person's offspring to Bloom Syndrome.

February 19th 2015

Study Results Challenge CMS Position on Follow-Up Scans in Cancer Patients

Published in the Journal of Nuclear Medicine, the authors show that a fourth and subsequent follow-up PET/CT scan in lung cancer patients was associated with treatment change.

February 19th 2015

Biomarker That Could Predict Survival After CRC Surgery Discovered

Research scientists at the Macquarie University and Concord Repatriation General Hospital in Australia have discovered that expression of the cell surface protein uPAR can predict survival after colorectal cancer (CRC) surgery. The study found that patients expressing uPAR may have undetectable cancer metastasis and dramatically poorer survival.

February 19th 2015

Gardasil 9 Offers Broader Protection, a Global Study Reports

Published in the New England Journal of Medicine, the multinational study found that Gardasil 9, 100% effective against 9 strains of HPV, can prevent the occurrence of 85%-90% of HPV-related cancers.

February 18th 2015

Phyllis Torda Championed Improved Quality Measurement Guidelines in Oncology

On February 16, after living with metastatic breast cancer, Phyllis Torda, 63, vice president of the Quality Solutions Group at the National Committee for Quality Assurance, passed away.

February 18th 2015

Balancing Value, Pathways, and Innovation in Healthcare

As specialty drug costs, formulary wars, and reimbursement models grab headlines everyday, we need to take a step back and visualize how all of this might impact innovation and whether the patient stands to lose in the process.

February 18th 2015

FDA Expands Indication for Revlimid in Multiple Myeloma

Laura Joszt, MA

The combination of Revlimid with dexamethasone, previously approved for treatment in patients with multiple myeloma who received at least 1 prior treatment, has received FDA approval for use in newly diagnosed multiple myeloma patients.

February 18th 2015

Study Identifies Potential Biomarker for Cabazitaxel Response in CRPC

The study published in Clinical Cancer Research elucidated an in vitro mechanism that could explain why cabazitaxel is more effective in some prostate cancer patients. The study also identified a biomarker that could provide precision medicine for a subset of patients.

February 17th 2015

Oncologist to Launch Social Media Campaign Against Cost of Cancer Drugs

Following his collaboration with other research scientists to protest the cost of cancer drugs, Hagop Kantarjian, MD, from the MD Anderson Cancer Center has now turned to patients.

February 17th 2015

Doctors Need to Be Tech Savvy, Report Suggests

The survey, conducted by salesforce.com, showed that 71% patients want their doctor to use a mobile application to schedule appointments, share health data, and manage preventive care; 60% patients reported an interest in using telehealth in place of in-person visits.

February 17th 2015

Cancer Patients Associated Shared-Decision Making With Quality Care

Laura Joszt, MA

Cancer patients with less involvement in their treatment decisions are less likely to report excellent quality of care even if they prefer physician-controlled decisions, according to a study in JAMA Oncology.

February 17th 2015

Study Urges Lung Cancer Trials to Include Survivors

The study, published in the Journal of the National Cancer Institute, found that having a prior cancer diagnosis did not affect outcomes among the patients with advanced lung cancer, which means these patients should be allowed to take part in clinical trials of new lung cancer treatments.

February 16th 2015

Improving the Value of Immune-Based Therapies

Richard W. Joseph, MD

February 16th 2015

Issues Impacting Stakeholder Adoption of Immuno-Oncology

Bruce Feinberg, DO

February 16th 2015

New Standards of Care in the Management of Prostate Cancer

Surabhi Dangi-Garimella, PhD

February 16th 2015

Payers Evaluate the Clinical Utility of Diagnostic Tests

Surabhi Dangi-Garimella, PhD

February 16th 2015

Innovation and the Role of Alternative Markers of Efficacy

Sejal Saraiya, PharmD

February 16th 2015

The Use and Implementation of Standardized Treatment Pathways

Sejal Saraiya, PharmD

February 16th 2015

Arguments Taking Shape For and Against FDA Regulation of Diagnostic Tests

Mary K. Caffrey

February 16th 2015

HHS Announces New Oncology Care Management Initiative

Laura Joszt, MA

February 16th 2015

Surabhi Dangi-Garimella, PhD

February 16th 2015

Study Results Support Early Treatment With Abiraterone in Prostate Cancer

Surabhi Dangi-Garimella, PhD

February 16th 2015

ASCO Announces Partner for CancerLinQ Platform

Mary K. Caffrey

February 16th 2015

ASCO Demands Medicaid Reform

Surabhi Dangi-Garimella, PhD

February 16th 2015

Hormonal Imbalance in Adult Survivors of Pediatric Cranial Tumors Reported

Investigators at St. Jude Children's Research Hospital found that decades after undergoing cranial irradiation for childhood cancer, adult survivors remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life.

...

138 139 140 141 142 143 144 145 146

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions